An IL-6/STAT3/MR/FGF21 axis mediates heart-liver cross-talk after myocardial infarction

The liver plays a protective role in myocardial infarction (MI). However, very little is known about the mechanisms. Here, we identify mineralocorticoid receptor (MR) as a pivotal nexus that conveys communications between the liver and the heart during MI. Hepatocyte MR deficiency and MR antagonist spironolactone both improve cardiac repair after MI through regulation on hepatic fibroblast growth factor 21 (FGF21), illustrating an MR/FGF21 axis that underlies the liver-to-heart protection against MI. In addition, an upstreaming acute interleukin-6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) pathway transmits the heart-to-liver signal to suppress MR expression after MI. Hepatocyte Il6 receptor deficiency and Stat3 deficiency both aggravate cardiac injury through their regulation on the MR/FGF21 axis. Therefore, we have unveiled an IL-6/STAT3/MR/FGF21 signaling axis that mediates heart-liver cross-talk during MI. Targeting the signaling axis and the cross-talk could provide new strategies to treat MI and heart failure.

[1]  L. Hui,et al.  Hepatic P38 Activation Modulates Systemic Metabolism Through Fgf21-Mediated Interorgan Communication. , 2021, Diabetes.

[2]  M. Ricote,et al.  Untangling the Cooperative Role of Nuclear Receptors in Cardiovascular Physiology and Disease , 2021, International journal of molecular sciences.

[3]  G. Bakris,et al.  Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine , 2020, European heart journal.

[4]  D. Goldstein,et al.  Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6 , 2020, Nature Reviews Cardiology.

[5]  I. Manabe,et al.  Organ System Crosstalk in Cardiometabolic Disease in the Age of Multimorbidity , 2020, Frontiers in Cardiovascular Medicine.

[6]  L. Brunsveld,et al.  Nuclear receptor crosstalk — defining the mechanisms for therapeutic innovation , 2020, Nature Reviews Endocrinology.

[7]  T. Burris,et al.  SR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by targeting the cardiac inflammasome , 2019, Communications Biology.

[8]  T. Long,et al.  IL-6 knockout ameliorates myocardial remodeling after myocardial infarction by regulating activation of M2 macrophages and fibroblast cells. , 2019, European review for medical and pharmacological sciences.

[9]  Jian-Dong Jiang,et al.  Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases , 2019, Nature Communications.

[10]  S. Javadov,et al.  Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases , 2018, International journal of molecular sciences.

[11]  F. Jaisser,et al.  Mineralocorticoid Receptor and Cardiovascular Disease , 2018, American journal of hypertension.

[12]  S. Sarcar,et al.  Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9 , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  B. C. Bernardo,et al.  Understanding Key Mechanisms of Exercise-Induced Cardiac Protection to Mitigate Disease: Current Knowledge and Emerging Concepts. , 2018, Physiological reviews.

[14]  A. Sato,et al.  Rev-erb agonist improves adverse cardiac remodeling and survival in myocardial infarction through an anti-inflammatory mechanism , 2017, PloS one.

[15]  L. Scott.  Tocilizumab: A Review in Rheumatoid Arthritis , 2017, Drugs.

[16]  S. Rajagopalan,et al.  The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature , 2017, American Journal of Nephrology.

[17]  C. Li,et al.  Deletion of Macrophage Mineralocorticoid Receptor Protects Hepatic Steatosis and Insulin Resistance Through ERα/HGF/Met Pathway , 2017, Diabetes.

[18]  C. Weber,et al.  Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype , 2016, European heart journal.

[19]  P. Ponikowski,et al.  A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease , 2016, European heart journal.

[20]  E. Olson,et al.  Bone and Muscle Endocrine Functions: Unexpected Paradigms of Inter-organ Communication , 2016, Cell.

[21]  W. Tang,et al.  Reverse Remodeling and Prognosis Following Kidney Transplantation in Contemporary Patients With Cardiac Dysfunction. , 2015, Journal of the American College of Cardiology.

[22]  C. Parikh,et al.  Reverse Left Ventricular Remodeling After Kidney Transplantation: Unraveling the Complex Autointoxication of Uremia. , 2015, Journal of the American College of Cardiology.

[23]  F. Villarroya,et al.  FGF21 and Cardiac Physiopathology , 2015, Front. Endocrinol..

[24]  P. Galuppo,et al.  Efficacy of mineralocorticoid receptor antagonism in the acute myocardial infarction phase: eplerenone versus spironolactone , 2015, ESC heart failure.

[25]  N. Rose,et al.  The varying faces of IL-6: From cardiac protection to cardiac failure. , 2015, Cytokine.

[26]  L. Solt,et al.  Suppression of atherosclerosis by synthetic REV-ERB agonist. , 2015, Biochemical and biophysical research communications.

[27]  Li-Qun Zhang,et al.  Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia. , 2012, American journal of physiology. Heart and circulatory physiology.

[28]  Satchidananda Panda,et al.  Regulation of Circadian Behavior and Metabolism by Rev-erbα and Rev-erbβ , 2012, Nature.

[29]  F. V. van Nieuwenhoven,et al.  PPARs as therapeutic targets in cardiovascular disease , 2010, Expert opinion on therapeutic targets.

[30]  S. Kozma,et al.  Differences in Wound Healing in Mice with Deficiency of IL-6 versus IL-6 Receptor , 2010, The Journal of Immunology.

[31]  Shu Q. Liu,et al.  Liver cell-mediated alleviation of acute ischemic myocardial injury. , 2010, Frontiers in bioscience.

[32]  S. Yamasaki,et al.  Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis , 2011, Rheumatology International.

[33]  S. Kliewer,et al.  FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response , 2009, Proceedings of the National Academy of Sciences.

[34]  R. Flavell,et al.  Role of STAT3 in liver regeneration: survival, DNA synthesis, inflammatory reaction and liver mass recovery , 2007, Laboratory Investigation.

[35]  J. Flier,et al.  Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. , 2007, Cell metabolism.

[36]  M. Harmsen,et al.  Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. , 2007, The American journal of pathology.

[37]  H. Haas,et al.  Loss of the limbic mineralocorticoid receptor impairs behavioral plasticity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Lippmann,et al.  Resolution of adult respiratory distress syndrome after recovery from fulminant hepatic failure. , 1999, The American journal of the medical sciences.

[39]  M. Magnuson,et al.  Dual Roles for Glucokinase in Glucose Homeostasis as Determined by Liver and Pancreatic β Cell-specific Gene Knock-outs Using Cre Recombinase* , 1999, The Journal of Biological Chemistry.

[40]  W. Wall,et al.  Resolution of the adult respiratory distress syndrome following colectomy and liver transplantation. , 1990, Chest.

[41]  G. Hoyer,et al.  Pharmacokinetics and metabolism of mespirenone, a new aldosterone antagonist, in rat and cynomolgus monkey. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.